IP Library › Granted Patent US 12,421,309
Granted Patent B2
US 12,421,309 · App. 17/299,156 · Granted Sep 23, 2025

Anti-TM4SF4 antibody and uses thereof

Inventors: In Gyu Kim (Daejeon, KR); Rae Kwon Kim (Sejong, KR); Jai Ha Lee (Daejeon, KR); Chang Kyu Heo (Daejeon, KR); Yeon Jee Kahm (Hwaseong-si, KR); Byung Chul Shin (Seoul, KR); Eun Wie Cho (Daejeon, KR); Chun Jeih Ryu (Seoul, KR); Min Kyu Kim (Seoul, KR); Mun Ju Choi (Seoul, KR)
Assignee: KOREA ATOMIC ENERGY RESEARCH INSTITUTE
C07K16/28A61P11/00A61P35/00A61K2039/505C07K2317/21C07K2317/34C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,309
App. No.
17/299,156
Granted
Sep 23, 2025
Kind
B2
Abstract

The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.

Claims (21)

1. An antibody or antigen-binding fragment thereof that specifically binds to TransMembrane 4 Superfamily Member 4 (TM4SF4), wherein

the antibody binds to an epitope region including an amino acid sequence of SEQ ID NO: 2, wherein the antibody is

(a) an antibody including a heavy chain variable region having CDR-H1 including the amino acid sequence of SEQ ID NO: 3, CDR-H2 including the amino acid sequence of SEQ ID NO: 4, and CDR-H3 including the amino acid sequence of SEQ ID NO: 5; and a light chain variable region having CDR-L1 including the amino acid sequence of SEQ ID NO: 6, CDR-L2 including the amino acid sequence of SEQ ID NO: 7, and CDR-L3 including the amino acid sequence of SEQ ID NO: 8; or

(b) an antibody including a heavy chain variable region having CDR-H1 including the amino acid sequence of SEQ ID NO: 9, CDR-H2 including the amino acid sequence of SEQ ID NO: 10, and CDR-H3 including the amino acid sequence of SEQ ID NO: 11; and a light chain variable region having CDR-L1 including the amino acid sequence of SEQ ID NO: 12, CDR-L2 including the amino acid sequence of SEQ ID NO: 13, and CDR-L3 including the amino acid sequence of SEQ ID NO: 14.

2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody includes a heavy chain variable region including the amino acid sequence of SEQ ID NO: 15; and a light chain variable region including the amino acid sequence of SEQ ID NO: 16.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody includes a heavy chain variable region including the amino acid sequence of SEQ ID NO: 19; and a light chain variable region including the amino acid sequence of SEQ ID NO: 20.

4. The antibody or antigen-binding fragment thereof of claim 1 , wherein

the antigen-binding fragment is Fab, F(ab′), F(ab′) 2 or Fv.

5. A nucleic acid molecule coding the antibody or antigen-binding fragment thereof of claim 1 .

6. An expression vector comprising the nucleic acid molecule of claim 5 .

7. A host cell comprising the expression vector of claim 6 .

8. A method for producing an antibody or antigen-binding fragment thereof comprising culturing the host cell of claim 7 .

9. A composition for detecting TM4SF4 comprising the antibody or antigen-binding fragment thereof of claim 1 .

10. A kit for detecting a TM4SF4 in a biological sample comprising the antibody or antigen-binding fragment thereof of claim 1 .

11. A method for detecting a TM4SF4 antigen comprising contacting the antibody or antigen-binding fragment thereof of claim 1 with a sample to be detected which is expected to include the TM4SF4 antigen.

12. A method for treating a TM4SF4 + cancer in a subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective dose of the antibody or antigen-binding fragment thereof of claim 1 ; and a pharmaceutically acceptable carrier.

13. The method for treating a TM4SF4 + cancer of claim 12 , wherein the treatment of cancer is to treat cancer chemical resistance, cancer recurrence, or cancer metastasis during or after cancer treatment.

14. The method for treating a TM4SF4 + cancer of claim 12 , wherein the TM4SF4 + cancer is at least one selected from the group consisting of lung cancer, gastric cancer, Ovarian cancer, cervical cancer, breast cancer, pancreatic cancer, colon cancer, rectal cancer, esophageal cancer, skin cancer, thyroid cancer, kidney cancer, liver cancer, head and neck cancer, bladder cancer, prostate cancer, blood cancer, multiple myeloma, acute myelogenous leukemia, malignant lymphoma, thymus cancer, osteosarcoma, fibrotic tumor and brain cancer.

15. A method for inhibiting growth of TM4SF4 + cancer stem cells comprising contacting the antibody or antigen-binding fragment thereof of claim 1 with the TM4SF4 + cancer stem cells.

16. A method for improving chemoradiation therapy of TM4SF4 + cancer cells comprising contacting the antibody or antigen-binding fragment thereof of claim 1 with the TM4SF4 + cancer cells.

17. The method for improving chemoradiation therapy of TM4SF4 + cancer cells of claim 16 , wherein the antibody or antigen-binding fragment thereof enhances the sensitivity to radiation of the TM4SF4 + cancer cells including TM4SF4 + cancer stem cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2021
From: KIM, IN GYU; KIM, RAE KWON; LEE, JAI HA; HEO, CHANG KYU; KAHM, YEON JEE; SHIN, BYUNG CHUL; CHO, EUN WIE; RYU, CHUN JEIH; KIM, MIN KYU; CHOI, MUN JU
To: KOREA ATOMIC ENERGY RESEARCH INSTITUTE
Reel/Frame 056417/0099 →
Priority Claims (1)
KR 10-2019-0162068 · Dec 6, 2019 · national
Continuity (1)
Related Publication 20230002485A1 · Jan 5, 2023
References Cited (87)
US 7785801B2 · Türeci et al. · 2010 [cited by applicant]
US 8445722B2 · Park et al. · 2013 [cited by applicant]
US 8778901B2 · Park et al. · 2014 [cited by applicant]
US 9072698B2 · Park et al. · 2015 [cited by applicant]
US 9075064B2 · Kim et al. · 2015 [cited by applicant]
US 9255131B2 · Türeci et al. · 2016 [cited by applicant]
US 9334331B2 · Igawa · 2016 [cited by examiner]
US 9533043B2 · Türeci et al. · 2017 [cited by applicant]
US 10059773B2 · Zhang et al. · 2018 [cited by applicant]
US 10421807B2 · Gonzales · 2019 [cited by examiner]
US 10724103B2 · Türeci et al. · 2020 [cited by applicant]
US 20020115057A1 · Young · 2002 [cited by applicant]
US 20080193454A1 · Tureci et al. · 2008 [cited by applicant]
US 20090130102A1 · Weaver et al. · 2009 [cited by applicant]
US 20100068730A1 · Park et al. · 2010 [cited by applicant]
US 20100081638A1 · Lee et al. · 2010 [cited by applicant]
US 20110014628A1 · Türeci et al. · 2011 [cited by applicant]
US 20110177098A1 · Sussel et al. · 2011 [cited by applicant]
US 20110318361A1 · Park et al. · 2011 [cited by applicant]
US 20120282619A1 · Park et al. · 2012 [cited by applicant]
US 20140120085A1 · Türeci et al. · 2014 [cited by applicant]
US 20140234326A1 · Kim et al. · 2014 [cited by applicant]
US 20160193335A1 · Tureci et al. · 2016 [cited by applicant]
US 20160362498A1 · Zhang et al. · 2016 [cited by applicant]
US 20170073395A1 · Finlay et al. · 2017 [cited by applicant]
US 20180169236A1 · Tureci et al. · 2018 [cited by applicant]
US 20180346585A1 · Zhang et al. · 2018 [cited by applicant]
US 20190231872A1 · Kwon et al. · 2019 [cited by applicant]
CN 101748122A · 2010 [cited by applicant]
EP 1498424A2 · 2005 [cited by applicant]
JP 2007537197A · 2007 [cited by applicant]
JP 2008283945A · 2008 [cited by applicant]
JP 2009530422A · 2009 [cited by applicant]
JP 2014528944A · 2014 [cited by applicant]
KR 1020080052391A · 2008 [cited by applicant]
KR 1020080058022A · 2008 [cited by applicant]
KR 100906145B1 · 2009 [cited by applicant]
KR 1020130033075A · 2013 [cited by applicant]
KR 101314828B1 · 2013 [cited by applicant]
KR 101836392B1 · 2018 [cited by applicant]
KR 1020210071856A · 2021 [cited by applicant]
WO 2004073657A2 · 2004 [cited by applicant]
WO 2013047941A1 · 2013 [cited by applicant]
WO 2021112640A1 · 2021 [cited by applicant]
Al Qaraghuli et al. (2020, Nature Scientific Reports 10:13969). [cited by examiner]
Edwards et al. (2003, JMB 334:103-118). [cited by examiner]
Lloyd et al. (2009, Protein Engineering, Eng. Design & Selection 22(3): 159-168). [cited by examiner]
Goel et al. (2004, J. Immunol. 173: 7358-7367). [cited by examiner]
Khan et al. (2014, J. Immunol. 192: 5398-5405). [cited by examiner]
Poosarla et al. (2017, Biotechn. Bioeng. 114(6): 1331-1342). [cited by examiner]
Rabia, et al. (2018, Biochemical Engineering Journal 137:365-374). [cited by examiner]
International Search Report dated Mar. 11, 2021 for corresponding International Patent Application No. PCT/KR2020/017699. [cited by applicant]
Written Opinion dated Mar. 11, 2021 for corresponding International Patent Application No. PCT/KR2020/017699. [cited by applicant]
Soo-Im Choi et al., “TM4SF4 overexpression in radiation-resistant lung carcinoma cells activates IGF1R via elevation of IGF1,” Oncotarget, Sep. 8, 2014, pp. 9823-9837, vol. 5, No. 20, cited in NPL Nos. 1 and 2, and the … [cited by applicant]
GenBank Accession No. AAP36961.1, “ [cited by applicant]
Soo-Im Choi et al., “Osteopontin production by TM4SF4 signaling drives a positive feedback autocrine loop with the STAT3 pathway to maintain cancer stem cell-like properties in lung cancer cells,” Oncotarget, Sep. 18, 2… [cited by applicant]
Charles Yanofsky et al., “Repression is Relieved I3efore Attenuation in the trp Operon of [cited by applicant]
Ira Herskowitz et al., “The Lysis-Lysogeny Decision of Phage Lambda: Explicit Programming and Reponsiveness,” Ann. Rev. Genet, 1980, pp. 399-445, vol. 14, cited in the Specification. [cited by applicant]
Hyun-Woo Park et al., “Optimization of Cry3A Yields in Bacillus thuringiensis by use of Sporulation-Dependent Promoters in Combination with the STAB-SD mRNA Sequence,” Applied and Environmental Microbiology, Oct. 1998, … [cited by applicant]
Alejandra Bravo et al., “Analysis of crylAa expression in sigE and sigK mutants of Bacillus thuringiensis,” Mol Gen Genet, 1996, pp. 734-741, vol. 250, cited in the Specification. [cited by applicant]
Zhongde Wang et al., “Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3X to 5X exonuclease activity,” Journal… [cited by applicant]
Ying Li et al., “Human tetraspanin transmembrane 4 superfamily member 4 or intestinal and liver tetraspan membrane protein is overexpressed in hepatocellular carcinoma and accelerates tumor cell growth,” Acta Biochim Bi… [cited by applicant]
W. Franklin et al., “Detection of RNA biomarkers in sputum of lung cancer patients and high risk smokers,” 11th world conference on Lung cancer, Jul. 3-6, 2005, Barcelona, Spain, abstract p. 245. [cited by applicant]
Dandrea et al., “The Transcriptosomal Response of Human A549 Lung Cells to a Hydrogen Peroxide-Generating System: Relationship to DNA Damage, Cell Cycle Arrest, and Caspase Activation,” Free Radical Biology & Medicine, … [cited by applicant]
Nakamura et al., “Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma,” Oncogene, Feb. 20, 2006, vol. 25, pp. 4245-4255. [cited by applicant]
Qiu et al., “Overexpression of the gene for transmembrane 4 superfamily member 4 accelerates liver damage in rats treated with CCI4,” Journal of Hepatology, Oct. 2, 2006, vol. 46, pp. 266-275; cited in NPL Nos. 15 & 16. [cited by applicant]
Juan Angel Fresno Vara et al., “PI3K/Akt signalling pathway and cancer,” Cancer Treatment Reviews, Apr. 2004, vol. 30, No. 2, pp. 193-204. [cited by applicant]
Rundhaug, “Matrix Metalloproteinases, Angiogenesis, and Cancer,” Clinical Cancer Research, Feb. 2003, vol. 9, No. 2, pp. 551-554. [cited by applicant]
Wright et al., “The L6 membrane proteins—A new four-transmembrane superfamily,” Protein Science, 2000, vol. 9, No. 8, pp. 1594-1600. [cited by applicant]
Zevian et al., “Structure-Function Analysis of Tetraspanin CD151 Reveals Distinct Requirements for Tumor Cell ˜,” The Journal of Biological Chemistry, Dec. 2, 2010, vol. 286, No. 9, pp. 7496-7506. [cited by applicant]
Lee et al., “Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma,” The Journal of Clinical Investigation, Apr. 2008, vol. 118, No. 4, pp. 1354-1366. [cited by applicant]
Choi et al., “Cooperation between integrin alpha 5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity,” Blood, Nov. 25, 2008, vol. 113, No. 8, pp. 1845-1855. [cited by applicant]
Lui et al., “Molecular cloning of a cDNA for rat TM4SF4, a homolog of human il-TMP(TM4SF4), and enhanced expression of the corresponding gene in regenerating rat liver,” Biochimica et Biophysica Acta, 2001, vol. 1518, p… [cited by applicant]
Anderson et al., “The L6 domain tetraspanin Tm4sf4 regulates endocrine pancreas differentiation and directed cell migration,” Development, 2011, vol. 138, No. 15, pp. 3213-3224. [cited by applicant]
Japanese Office Action issued on Jun. 28, 2022, in connection with the Japanese Patent Application No. 2021-542571, 7 pages, along with English machine translation. [cited by applicant]
International Search Report issued Sep. 20, 2022, corresponding to International Patent Application No. PCT/KR2022/008570, 4 pages. [cited by applicant]
Written Opinion issued Oct. 12, 2012, corresponding to International Patent Application No. PCT/KR2011/007900, 10 pages, along with English machine translation. [cited by applicant]
International Search Report issued Oct. 12, 2012, corresponding to International Patent Application No. PCT/KR2011/007900, 8 pages, along with English machine translation. [cited by applicant]
Written Opinion issued Mar. 11, 2021, corresponding to International Patent Application No. PCT/KR2020/017699, 6 pages, along with English machine translation. [cited by applicant]
International Search Report issued Mar. 11, 2021, corresponding to International Patent Application No. PCT/KR2020/017699, 8 pages, along with English machine translation. [cited by applicant]
Jung, Kyungsoo et al., “TM4SF4 and LRRK2 are Potential Therapeutic Targets in Lung and Breast Cancers through Outlier Analysis”, Cancer Res Treat, 2021, vol. 53, Issue 1, pp. 9-24. [cited by applicant]
The Extended European Search Report dated Nov. 18, 2024 for corresponding European Patent Application No. 22825362.1 (8 pages). [cited by applicant]
Office Action dated Jan. 7, 2025 for corresponding Japanese Patent Application No. 2023-578042, along with an English translation (12 pages). [cited by applicant]
Yoonjoo Choi et al., “Antibody humanization by structure-based computational protein design”, mAbs, vol. 7, No. 6, Aug. 7, 2015, pp. 1045-1057, cited in NPL No. 1. [cited by applicant]
Johnathan D. Guest et al., “An Expanded Benchmark for Antibody-Antegen Docking and Affinity Prediction Reveals Insights into Antibody Recognition Determinants”, Structure, vol. 29, No. 6, Jun. 3, 2021 (39 pages), cited … [cited by applicant]
Toshio Akimoto, “Human Reshaped Antibodies”, Journal of the Crystallographic Society of Japan, vol. 37, 1995, pp. 134-136, cited in NPL No. 2, with English abstract. [cited by applicant]
Kouhei Tsumoto, “Dissection of antibody-antigen interactions for development of antibodies”, Drug Delivery System, vol. 28, Issue 5, 2013, pp. 412-423, cited in NPL No. 2, with English abstract. [cited by applicant]